SOURCE: BioMedReports


March 15, 2011 13:15 ET

Report: CBLI Officials in Touch With Appropriate Government Agencies as Japan's Nuclear Reactors Remain Unstable

LOS ANGELES, CA--(Marketwire - March 15, 2011) -  Officials at Cleveland Biolabs (NASDAQ: CBLI) continue to monitor the situation in Japan as U.S. Navy personnel have begun taking precautionary measures after instruments aboard an aircraft carrier docked in Japan detected some levels of radioactivity from the Fukushima Daiichi nuclear plant.

Various news reports out of that country indicate that workers continue scrambling to cool down fuel rods and prevent a full meltdown in three reactors at the earthquake-hit Fukushima Daiichi plant.

Japanese Prime Minister Naoto Kan warned Tuesday that the risk of further releases of radioactive material from the plant remains "very high."

"It really is difficult to interpret from the news what really is happening, government officials claim the situation is under control," said Cleveland Biolabs' CEO Michael Fonstein in an interview with BioMedReports. "The situation could deteriorate and someone should provide doses to protect the workers, so that they can be protected in case of exposure, regardless of deterioration. We believe our drug can help."

This past weekend, the company spent some time reaching out to officials, through the appropriate channels, to let them know that they were willing to donate doses of their CBLB502 radiation antidote. Extensive studies have demonstrated that CBLB502 is a very effective and non-toxic anti-radiation treatment which can increase the survival rates significantly after high doses of radiation.

"You know that there are certain U.S. agencies which are responsible for our own counter-measures and these same agencies are also responsible for dealing with international issues in this area, so we have been following clear protocols to make them aware that we have doses of CBLB502 which could be made available for potential emergency use."

"As far as getting into details as to which agencies we have been in contact with, I can only use the term 'appropriate U.S. agencies,'" explains Fonstein. "At this point I would not be comfortable to be more specific. We have actually made them aware that we do have doses available."

In addition, while the company said they had no additional update to provide, they continue to expect news about a pending $50+ million dollar grant from due from the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS). These monies are to be allocated for continued development of CBLB502 and will eventually lead to an RFP for the U.S. National Stockpile.

The full special report and interview with the Chief Executive Officer of Cleveland Biolabs is now available at:

Investors interested in accessing BioMedReports' complete database of clinical trials and upcoming FDA decisions can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Contact Information

  • Media Contacts Only:

    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556